WO2007047698A3 - Methods and compositions for the treatment of neuropsychiatric and addictive disorders - Google Patents

Methods and compositions for the treatment of neuropsychiatric and addictive disorders Download PDF

Info

Publication number
WO2007047698A3
WO2007047698A3 PCT/US2006/040598 US2006040598W WO2007047698A3 WO 2007047698 A3 WO2007047698 A3 WO 2007047698A3 US 2006040598 W US2006040598 W US 2006040598W WO 2007047698 A3 WO2007047698 A3 WO 2007047698A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
neuropsychiatric
treatment
addictive disorders
Prior art date
Application number
PCT/US2006/040598
Other languages
French (fr)
Other versions
WO2007047698A2 (en
Inventor
Daryl W Hochman
John J Partridge
Original Assignee
Neurotherapeutics Pharma Llc
Daryl W Hochman
John J Partridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/251,724 external-priority patent/US8008283B2/en
Priority claimed from US11/549,274 external-priority patent/US20070149526A1/en
Application filed by Neurotherapeutics Pharma Llc, Daryl W Hochman, John J Partridge filed Critical Neurotherapeutics Pharma Llc
Priority to US12/090,301 priority Critical patent/US20090215754A1/en
Priority to CA002625362A priority patent/CA2625362A1/en
Priority to EP06826134A priority patent/EP1937242A4/en
Publication of WO2007047698A2 publication Critical patent/WO2007047698A2/en
Publication of WO2007047698A3 publication Critical patent/WO2007047698A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+-K+-2Cl- (NKCC) cotransporter. In certain embodiments, the Na+-K+-2Cl- co-transporter is NKCC1.
PCT/US2006/040598 1998-12-23 2006-10-17 Methods and compositions for the treatment of neuropsychiatric and addictive disorders WO2007047698A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/090,301 US20090215754A1 (en) 1998-12-23 2006-10-17 Methods and compositions for the treatment of neuropsychiatric and addictive disorders
CA002625362A CA2625362A1 (en) 2005-10-17 2006-10-17 Methods and compositions for the treatment of neuropsychiatric and addictive disorders
EP06826134A EP1937242A4 (en) 2005-10-17 2006-10-17 Methods and compositions for the treatment of neuropsychiatric and addictive disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US72756405P 2005-10-17 2005-10-17
US72731805P 2005-10-17 2005-10-17
US60/727,318 2005-10-17
US11/251,724 2005-10-17
US11/251,724 US8008283B2 (en) 1998-12-23 2005-10-17 Methods and compositions for the treatment of neuropsychiatric disorders
US60/727,564 2005-10-17
US11/549,274 US20070149526A1 (en) 2005-10-17 2006-10-13 Diuretic and diuretic-like compound analogs
US11/549,274 2006-10-13

Publications (2)

Publication Number Publication Date
WO2007047698A2 WO2007047698A2 (en) 2007-04-26
WO2007047698A3 true WO2007047698A3 (en) 2007-07-05

Family

ID=37963225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040598 WO2007047698A2 (en) 1998-12-23 2006-10-17 Methods and compositions for the treatment of neuropsychiatric and addictive disorders

Country Status (2)

Country Link
EP (1) EP1937242A4 (en)
WO (1) WO2007047698A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042314A1 (en) * 2015-09-11 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of post-traumatic epilepsies
US11666547B2 (en) * 2019-06-28 2023-06-06 Northwestern University Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5162325A (en) * 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
JP2009511629A (en) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ， インコーポレイテッド Analogues of diuretic-like compounds useful in the regulation of central nervous system diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5162325A (en) * 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1937242A4 *

Also Published As

Publication number Publication date
EP1937242A4 (en) 2011-06-15
EP1937242A2 (en) 2008-07-02
WO2007047698A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2006110187A3 (en) Methods and compositions for the treatment of anxiety disorders
WO2006124913A3 (en) Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
WO2007112000A3 (en) Treatment of pain
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA92503C2 (en) 5-(phenylisoxazolylethoxy)-triazol-3-yl-substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders
WO2006091395A3 (en) Inhibitors of akt activity
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
WO2006135627A3 (en) Inhibitors of akt activity
WO2006110638A3 (en) Inhibitors of akt activity
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
TW200531689A (en) Therapeutic agents
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
MX2007014920A (en) Combination therapy comprising diaryl ureas for treating diseases.
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TW200611695A (en) Pyrrolopyridine derivatives
BRPI0607536A2 (en) pain treatment
WO2007046097A3 (en) Topical compositions for the treatment of depilation-induced skin irritation or prevention thereof
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
TW200503668A (en) Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2006068796A3 (en) Inhibitors of akt activity
TW200726763A (en) Novel compound
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006826134

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2625362

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004951

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12090301

Country of ref document: US